



Rec'd PCT/PTO 09 OCT 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Yip, et al.  
SERIAL NO : 09/744,628  
FILED : January 25, 2001  
TITLE : IDENTIFICATION OF COMPOUNDS FOR MODULATING DIMERIC RECEPTORS

Docket No. : P04885US1

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please enter the following preliminary amendment into the specification:


In the Specification

The paragraph beginning at page 2, line 3 has been replaced with the following:

A1  
Diabetes is presently treated by insulin replacement therapy. This treatment has been very successful, but it still has problems such as glycemic control. Poor glycemic control can cause retinopathy, poor blood circulation and the other problems associated with diabetes. It is also difficult to formulate insulin for slow release. Modified insulins have been created in an attempt to address problems with insulin therapy. In some cases, "super-insulins" have been created to increase the activation of insulin receptor by its ligand. In other cases, binding to insulin receptor is not substantially increased, but the ligand has more favourable formulation properties. For example, in Humalog™ (SEQ ID NO:3 and SEQ ID NO:4), a lysine and a proline in insulin are switched to provide more favourable solubility characteristics.

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this document and the documents referred to as enclosed therein are being deposited with the United States Postal Service as First Class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on this 1 day of October, 2001.

  
Heidi S. Nebel